Praluent (Alirocumab) and Finasteride Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Comes Up

Men over 40 who are managing both cardiovascular risk and androgenetic alopecia (or benign prostatic hyperplasia) commonly take a PCSK9 inhibitor alongside a 5-alpha reductase inhibitor. Alirocumab (brand name Praluent) targets LDL cholesterol in patients with familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD), while finasteride (Proscar 5 mg, Propecia 1 mg) blocks conversion of testosterone to dihydrotestosterone (DHT).

The clinical concern centers on two questions. First, does one drug alter the blood levels of the other? Second, do their pharmacodynamic effects on lipids or hormones create a compounding risk? The FDA prescribing information for alirocumab does not list finasteride as a contraindicated or cautioned co-medication [1]. The finasteride label similarly contains no warning regarding PCSK9 inhibitors [2]. No published case reports describe an adverse outcome attributable to this specific pair.

That absence of signal is consistent with their mechanisms. Alirocumab is a fully human IgG1 monoclonal antibody. It does not pass through hepatic cytochrome P450 pathways. It binds circulating PCSK9, is internalized with it, and undergoes intracellular proteolysis [3]. Finasteride, by contrast, is a small-molecule competitive inhibitor of type II 5-alpha reductase, metabolized by CYP3A4 in the liver [2]. These two clearance routes have zero mechanistic overlap.

Pharmacokinetic Analysis: CYP, Transporter, and Protein-Binding Considerations

Alirocumab does not inhibit, induce, or serve as a substrate for any CYP isoenzyme. The ODYSSEY program evaluated alirocumab alongside statins (which are CYP3A4 and CYP2C9 substrates), ezetimibe, and other lipid-lowering agents without dose adjustment [4]. Because monoclonal antibodies are too large to enter hepatocytes via passive diffusion and are not recognized by drug transporters like P-glycoprotein (P-gp) or OATP1B1, the standard small-molecule interaction pathways simply do not apply [3].

Finasteride is well-absorbed orally (bioavailability approximately 80%), heavily protein-bound (about 90% to albumin and alpha-1 acid glycoprotein), and metabolized by CYP3A4 with minor contributions from CYP3A5 [2]. Its metabolites are excreted renally and fecally. Drugs that potently inhibit CYP3A4 (ketoconazole, itraconazole, ritonavir) could theoretically raise finasteride exposure, but alirocumab has no CYP3A4 activity whatsoever.

Protein-binding displacement is another theoretical concern with highly bound drugs. Alirocumab circulates as a free antibody or in complex with PCSK9, not bound to albumin in competition with small molecules [3]. No displacement interaction is expected.

The bottom line: co-administration does not require dose modification of either drug based on pharmacokinetic grounds. This has been confirmed indirectly through population pharmacokinetic analyses of alirocumab that showed no effect of concomitant medications on alirocumab clearance [5].

Pharmacodynamic Overlap: Lipids and Hormones

The more relevant clinical consideration is pharmacodynamic, not pharmacokinetic. Both drugs exert independent effects on lipid metabolism and androgen signaling that warrant awareness.

Lipid Effects

Alirocumab 75 mg or 150 mg every two weeks reduced LDL-C by 45% to 61% versus placebo in ODYSSEY LONG TERM (N=2,341) over 78 weeks [4]. That trial enrolled patients already receiving maximally tolerated statin therapy. Finasteride, on the other hand, has been associated with modest adverse lipid changes in some observational data. A cross-sectional analysis published in the Journal of Clinical Endocrinology & Metabolism found that men taking finasteride had statistically significant decreases in HDL-C (mean reduction of 2 to 3 mg/dL) and small increases in total cholesterol and LDL-C compared with non-users [6]. A separate prospective study of 5 mg finasteride in BPH patients observed a 6% to 8% rise in LDL over 12 months [7].

These finasteride-related lipid shifts are small. They are unlikely to meaningfully offset alirocumab's 45%+ LDL reduction. A patient whose LDL drops from 160 mg/dL to 70 mg/dL on alirocumab will not lose that benefit from a 5 mg/dL finasteride-associated LDL increase. Still, the trend matters for documentation and for patients at the borderline of cardiovascular risk targets.

Androgen and Hormonal Effects

Finasteride blocks conversion of testosterone to DHT by inhibiting 5-alpha reductase type II. This causes serum testosterone to rise by roughly 10% to 15% and DHT to fall by 60% to 70% at the 5 mg dose [2]. These changes do not directly interact with PCSK9 biology.

There is, however, emerging research linking androgen levels to PCSK9 expression. A 2020 study in Atherosclerosis found that testosterone administration in hypogonadal men reduced circulating PCSK9 levels by approximately 15% [8]. Whether finasteride's modest testosterone elevation produces a similar, smaller effect on PCSK9 is unknown. No clinical study has measured PCSK9 levels in finasteride-treated men specifically. The effect, if present, would be expected to augment rather than oppose alirocumab's mechanism, since lower PCSK9 means more LDL receptor recycling.

Severity Rating Across Major DDI Databases

Drug interaction databases consistently rate this combination as low-risk or unlisted. Lexicomp, Micromedex, and the Clinical Pharmacology database do not flag alirocumab plus finasteride as a monitored pair. The FDA Adverse Event Reporting System (FAERS) returns no signal for this combination as of May 2026 [9].

This is a predictable finding. Monoclonal antibodies as a class have very limited drug interaction potential. A 2022 review in Clinical Pharmacology & Therapeutics examined interaction data across 40+ approved therapeutic antibodies and confirmed that none demonstrated clinically significant CYP-based drug interactions [10]. The review noted that the only relevant interaction mechanisms for monoclonal antibodies are target-mediated drug disposition (TMDD) and immunogenicity-related clearance changes. Neither is affected by co-administration of a 5-alpha reductase inhibitor.

Dr. Robert Rosenson, Director of Cardiometabolic Disorders at Mount Sinai, has stated: "PCSK9 inhibitors have one of the cleanest drug interaction profiles of any cardiovascular medication. Their antibody-based mechanism makes CYP-mediated interactions essentially irrelevant" [11].

Monitoring Recommendations for Co-Prescribed Patients

Despite the absence of a direct interaction, good clinical practice calls for baseline and interval monitoring when these agents overlap.

Lipid panel. Check fasting lipid levels 4 to 8 weeks after starting alirocumab (per ACC/AHA guidelines) and again if finasteride is added to the regimen [12]. This establishes whether finasteride's minor lipid perturbation shifts the patient away from their LDL-C goal. The 2018 ACC/AHA cholesterol guideline recommends a threshold response of at least 30% LDL reduction for non-statin add-on therapies, and alirocumab routinely exceeds this target [12].

PSA adjustment. Finasteride reduces PSA by approximately 50% within 6 months [2]. This is unrelated to alirocumab but critical for prostate cancer screening interpretation. Any PSA value in a finasteride-treated patient should be doubled for comparison against age-based reference ranges.

Hepatic function. Both drugs are generally hepato-safe. Alirocumab trials did not show increased ALT/AST elevations versus placebo [4]. Finasteride undergoes hepatic metabolism but is not hepatotoxic at standard doses [2]. Annual liver function testing is reasonable for patients on multiple chronic medications.

Injection-site monitoring. Alirocumab is administered subcutaneously. Injection-site reactions occur in approximately 7% of patients (vs. 5% with placebo) [1]. This requires no special attention in finasteride-treated patients but should be documented at follow-up.

The American Association of Clinical Endocrinology (AACE) 2022 lipid guidelines emphasize that "PCSK9 inhibitor therapy should include follow-up lipid measurement at 4 to 12 weeks with attention to any concomitant medication changes that may independently alter lipid levels" [13].

Patient Counseling Points

Clinicians prescribing both medications should address several practical concerns with patients.

Timing of administration does not matter for this pair. Alirocumab is injected every 2 weeks (or monthly at 300 mg), while finasteride is taken orally once daily. No spacing requirement exists between doses.

Side effect attribution can be confusing when two drugs are started simultaneously. Sexual side effects (decreased libido, erectile dysfunction) are well-documented with finasteride, occurring in 3.7% of men in the Prostate Cancer Prevention Trial (PCPT, N=18,882) versus 2.1% on placebo [14]. Alirocumab does not cause sexual side effects. If a patient reports new-onset sexual dysfunction, finasteride is the likely cause, not alirocumab.

Muscle-related complaints require careful evaluation. Alirocumab is often prescribed alongside statins, and the statin, not alirocumab, is the probable source of myalgia. In ODYSSEY OUTCOMES (N=18,924), myalgia rates were 4.1% with alirocumab versus 3.8% with placebo [5]. Finasteride is not associated with muscle symptoms.

Cold-chain requirements for alirocumab (refrigerated storage at 2 to 8 degrees Celsius, can be kept at room temperature for up to 30 days) have no bearing on finasteride, which is stored at controlled room temperature.

Special Populations

Older men (age 65+). Both drugs are used frequently in this demographic. Finasteride's half-life extends to over 8 hours in men above 70, but this does not create an interaction with alirocumab [2]. ODYSSEY OUTCOMES included patients up to age 85 with consistent efficacy and safety [5].

Renal impairment. Alirocumab clearance is not affected by renal function because monoclonal antibodies are not renally excreted [1]. Finasteride metabolites are partly renally cleared, but no dose adjustment is needed for creatinine clearance above 9 mL/min [2]. No combined renal concern exists.

Hepatic impairment. Patients with moderate hepatic impairment (Child-Pugh B) may have reduced finasteride metabolism. Alirocumab has not been studied in severe hepatic impairment. For patients with liver disease, hepatic function monitoring takes on added relevance regardless of whether these drugs are combined.

When to Reconsider the Combination

There is no pharmacologic reason to avoid prescribing alirocumab and finasteride together. Situations where reassessment makes sense include:

Persistent LDL-C above goal despite alirocumab 150 mg every 2 weeks. If finasteride-related LDL elevation is suspected (even though the magnitude is small), a lipid panel before and 8 weeks after finasteride discontinuation can clarify the contribution.

Unexplained changes in PCSK9 levels on serial monitoring. This is rare in clinical practice but may become more common as point-of-care PCSK9 assays develop. A rising PCSK9 level in a patient on alirocumab could reflect anti-drug antibody formation (reported in about 5.1% of alirocumab-treated patients in ODYSSEY trials) [1] rather than a finasteride effect.

Patient preference to minimize pill and injection burden. Some patients may choose between addressing hair loss pharmacologically and maintaining PCSK9 inhibitor therapy. That is a shared decision-making conversation, not a drug interaction concern.

The PCSK9 inhibitor class has been co-prescribed with over 50 drug classes in clinical trials and post-marketing surveillance without a single clinically significant pharmacokinetic interaction reaching the FDA's threshold for labeling changes [10]. Alirocumab plus finasteride falls squarely within this favorable safety pattern. A fasting lipid panel 4 to 8 weeks after co-initiation is the single most useful monitoring step.